An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome

Trial Profile

An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 May 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 23 Apr 2014 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
    • 23 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top